One Hotel Dr,

Boston,

MA,

US,

ZIP: 02128

Phone: +1 617 455 4188

The HER2 space continues to storm ahead of other oncology fields due to the overwhelming success of Enhertu and the continued satisfaction with Herceptin. As we enter 2023, the field shows no sign of slowing down and it is turning its attention to non-breast cancer types where Anti-HER2 therapeutics are already making massive strides. It’s not just ADCs either like the aforementioned successes; multispecific antibodies, cell therapy, and radiopharmaceuticals are bringing strong results for patients with various cancer types at various clinical stages. Demonstrating that there are many stones still unturned and plenty of opportunity still out there for developers with HER2 in mind.

This is the one-stop-shop for all challenges HER2. Tackle the challenges at the heart of treating HER2-expressing breast cancer and non-breast tumors. Overcome the development challenges to advance therapeutics of all varieties quickly through your pipeline, ADCs, immunotherapies, and radiopharmaceuticals alike.

Accompanying you from preclinical through to post-approval indication agnostic trials, this meeting has been designed to enable the field to expand the clinical utility of HER2 as a multi-tumor target with a multiple modality approach and an aspiration to push beyond the boundaries of breast cancer.

Tickets    https://go.evvnt.com/1820072-2?pid=1052
Brochure https://go.evvnt.com/1820072-3?pid=1052

Prices:
Drug Developer Pricing - Conference + 3 Workshops - Standard Rate USD 4946.00
Drug Developer Pricing - Conference Only - Standard Rate USD 2999.00
Solution Provider Pricing - Conference + 3 Workshops - Standard Rate USD 6046.00
Solution Provider Pricing - Conference Only - Standard Rate USD 3799.00
Academic Pricing - Conference + 3 Workshops - Standard Rate USD 4246.00
Academic Pricing - Conference Only - Standard Rate USD 2599.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Andy Bader, Chief Scientific Officer, Trimuvira Immunologics, Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics, Carl Barrett, Vice President - Translational Science and Oncology Institute of Management & Entrepreneurship Development, AstraZeneca, David Ferry, Senior Vice President of Clinical Development, Dragonfly Therapeutics, Gail Lewis, Senior Principal Scientist, Genentech, Gerold Meinhardt, Vice President, Asset & Portfolio Management, Daiichi Sankyo, Guido Würth, Global Head of Programs, Affibody AB, Haesong Park, Member of the Faculty of Medicine, Dana Farber Cancer Institute, Haifeng Bao, Chief Executive Officer, BiOnecure, Jay Mettetal, Senior Director - Oncology Bioscience, AstraZeneca, Jei Chae, Chief Business Development Officer, LegoChem Biosciences, Jennifer Wheler, Chief Medical Officer, Precirix, Manmeet Aluwhalia, Chief Scientific Officer, Baptist Cancer Institute, Mary Hu, Co-Chief Executive Officer, Lepu Biopharma, Michael Press, Professor / Harold E. Lee Chair in Cancer Research, University of Southern California, Riccardo Canevari, Chief Executive Officer, RadioPharm Theranostics, Sadhna Shankar, MD, MPH, Vice President of Early Phase, Clinical Research, Oncology, Eisai, Sam Cytryn, Principal Investigator, MSKCC, Shawn Zhang, Chief Scientific Officer, Ambrx, Shumin (Sam) Liu, Chief Executive Officer, Shenzhen Enduring Biotech, Simone Sredni, Director of Medical Diagnostics, AstraZeneca